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Background: The aim of this study was to estimate excess pneumonia and influenza 
(P&I) hospitalizations during influenza epidemics and measure their correlation with 
influenza vaccine coverage in the 65 and more years old, according to the type/sub-
type of influenza virus.
Methods: The study period comprised week 40/1998-40/2015. Age- specific weekly 
P&I hospitalizations (ICD- 9: 480- 487) as main diagnosis were extracted from the 
National Hospital Discharge database. Age- specific baseline hospitalization rates were 
estimated by autoregressive integrated moving average (ARIMA) model without time 
periods with excess hospitalizations. Excess hospitalizations were calculated by sub-
tracting expected hospitalization rates from the observed during influenza epidemic 
periods. Correlation between excess P&I hospitalizations and influenza vaccine cover-
age in the elderly was measured with Pearson correlation coefficient.
Results: The average excess P&I hospitalizations/season was 19.4/105 (range 0- 
46.1/105), and higher excess was observed in young children with <2 years (79.8/105) 
and	≥65	years	(68.3/105). In epidemics with A(H3) dominant, the highest excess hos-
pitalizations were observed among 65 and over. Seasons which influenza B or A(H1)
pdm09 dominance the highest excess was observed in children with <2 years. High 
negative correlation was estimated between excess hospitalizations associated with 
A(H3) circulation and vaccine coverage in the elderly (r	=	−.653;	95%	CI:	−0.950	to	
−0.137).
Conclusion:	Over	80%	of	the	influenza	epidemics	were	associated	with	excess	hospi-
talizations. However, excess P&I hospitalizations pattern differed from age group and 
circulating virus. This ecologic approach also identified a reduction in excess P&I as-
sociated with A(H3) circulation with increasing vaccine coverage in the elderly.
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1  | INTRODUCTION
Influenza viruses circulate every year, causing epidemics that are usu-
ally benign and mild for the human population but that can complicate 
into other diseases, like pneumonia. According to Wuerth et al (2016),1 
in the 2002- 2011 period, influenza was the fourth causative agent for 
pneumonia and approximately 9/100 000 of pneumonia hospitaliza-
tions had influenza as the etiological respiratory agent. However, as 
influenza laboratory diagnosis is not usually performed in all suspected 
cases, using these data underestimate the influenza impact.2,3 Taking 
this into consideration, the overall effect of influenza epidemics has 
been measured through indirect ecologic methods using the Serfling 
approach4 and Poisson, negative binomial regression and autoregres-
sive integrated moving average (ARIMA) models to estimate influenza- 
associated mortality or hospitalizations rates.5-9 There are two main 
approaches in estimating influenza- associated excesses: one based on 
statistical models that include influenza activity indicators as explana-
tory covariates; another does not consider covariates and by excluding 
from the estimating process all parts of the outcome time series where 
there is evidence of occurrence of some event that might influence 
the outcome.9 Both approaches have pros and cons. Using models 
with covariates allows estimating influenza- associated outcomes by 
virus type and subtype, but requires robust virological data.10 In the 
alternative, this specific data requirement is not needed and can be 
used provided that consistent mortality or hospitalization time series 
are available.10 However, there are limitations also in this approach. 
The lack of virological covariates in the model implies the assumption 
that all excess winter mortality is associated with influenza circula-
tion which may not be appropriate, leading therefore to a mortality 
overestimation.
The identification of influenza epidemics requires influenza sur-
veillance data, with information on influenza virus type, and influenza 
epidemic activity period.11,12 Also, and when available, the identifica-
tion of other events that contribute to mortality or hospitalizations 
distribution, like secular trend or seasonality, is desirable so to get a 
better fit of the model to the time series and improve the quality and 
the validity of the influenza attributable excess estimate.13
The influenza impact is particularly evident in specific groups, like 
the elderly, pregnant and those with chronic disease, with higher risk 
of complications associated with influenza infection leading to hos-
pitalization or death.14 For this high- risk group of individuals, yearly 
vaccination in the autumn is recommended in Portugal and in most 
EU countries, with the intention of reducing risk of complications, 
severe disease, and death.15,16 The influenza vaccine has proven to 
be moderately effective in reducing medically attended confirmed in-
fluenza.17 Using an ecologic approach, one would expect a reduction 
in excess hospitalizations/mortality with increasing vaccine coverage 
and this was already reported in previous influenza- related outcomes 
studies.18,19
In Portugal, there are several studies that associate this respiratory 
infection with excess pneumonia and influenza (P&I) and all- causes 
mortality.8,13 However, information on influenza impact on morbidity 
indicators, such as hospital admissions, is scarce and the knowledge 
of influenza impact and the role of immunization on hospitalizations 
is essential for a better resource management and for preparing miti-
gation measures.
Considering the Portuguese mainland context, this study aims to 
(i) estimate the excess number of P&I hospitalizations during influenza 
epidemics from seasons 1998- 1999 to 2014- 2015 and (ii) to measure 
their correlation with influenza vaccine coverage in the elderly (65 and 
more years old), according to the type/subtype of influenza virus pre-
dominant in each season.
2  | METHODS
A time series ecological study was conducted to estimate the baseline 
of weekly P&I hospitalizations free of influenza epidemics and esti-
mate excess P&I hospitalizations associated with influenza epidemics 
between 1998/1999 and 2014/2015 seasons.
2.1 | Hospital discharge data
Weekly hospitalizations with P&I as principal diagnosis, according to 
the International Classification of Disease (ICD 9: 480- 487), were ex-
tracted from the National Hospital Discharge database (1998- 2015). 
Weekly time series were disaggregated by age group: <2, 2- 4, 5- 14, 
15- 49, 50- 64, and 65 and more years.
2.2 | Influenza activity
The definition of influenza epidemic periods was based on in-
formation from the Portuguese Influenza Surveillance System. 
The influenza epidemic period, according information from the 
Portuguese Influenza Surveillance System, was defined as the pe-
riod with weekly estimates of influenza- like illness (ILI) incidence 
rates obtained by the Portuguese General Practitioner (GP) Sentinel 
Network (Rede Médicos- Sentinela) above the baseline with non- 
sporadic detections of influenza viruses.20 Taking this into consid-
eration, an influenza epidemic was identified in all seasons of the 
study period, exception for the 2005/2006 season. One week was 
added at the end of the influenza epidemic period to account for 
eventual delays on the impact.
Predominant virus circulating was provided by Portuguese 
Laboratory Network for the Diagnosis of Influenza Infection, namely 
by National Influenza Reference Laboratory, and was defined accord-
ing to Influenza Reporting Protocol.21 The threshold for dominance 
was	 set	 at	60%,	 and	 the	 threshold	 for	 codominance	 is	 set	between	
40%	and	60%.21
2.3 | Periods potentially associated with excess 
hospitalizations
These periods include the influenza epidemic (description above on 
Influenza activity), 2009 pandemic influenza,22 and heat wave peri-
ods (weeks in which two or more consecutive days had an average 
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maximum daily temperature above 32°C with an extra week to ac-
count the known delay of impact.13,23
2.4 | Influenza vaccine coverage rates
The influenza vaccine coverage (IVC) rates, for individuals with 65 and 
more years, were obtained from ECOS (Em Casa Observamos Saúde—At 
Home We Watch Health), a panel of approximately 1000 households on 
which a seasonal survey is carried out by computer- assisted telephone 
interview (CATI).24 These households were selected randomly from the 
national telephone directory and recruited considering the representa-
tiveness of Portuguese mainland families reachable by telephone.
2.5 | Methods to estimate the number of excess 
hospitalization associated with influenza epidemics
Age- specific baseline hospitalization rates were estimated by ARIMA 
model,25 after extracting from the time series the periods potentially 
associated with excess hospitalizations (defined above and presented 
on Table S1), using Flubase R package.26 ARIMA model is composed of 
3 terms: first, an autoregressive term (AR), in which the time series is 
regressed on itself at specific lag times; second, a moving average term 
(MA), in which the time series is regressed on the regression errors at spe-
cific lag times; and finally, an integration term that accounts for the non- 
stationarity of the time series. If the integrated component is present, 
the time series is differentiated on itself at specific lag periods; if I = 1, 
the	original	time	series	is	transformed	in	new	time	series	=	y(t)−y(t−1).
Using an automatic model identification algorithm included on the 
package, which recurs to a specific R package named forecast, the final 
models (Table S2) were selected.27
Excess hospitalization rates were calculated by subtracting P&I 
weekly hospitalization rates baseline, obtained through the model fit-
ting, from the observed weekly P&I hospitalization rates during influ-
enza epidemic periods (Figure 1).
Season	 excess	 P&I	 hospitalization	 rates	 95%	 confidence	 level	
were calculated by approximation to the normal distribution, using 
F IGURE  1 Weekly P&I hospitalization 
rate per 100 000 inhabitants and the 
respective estimated baseline and baseline 
upper limit in the absence of the impact of 
influenza epidemics from 1998 to 2015
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as standard error the product of the square root of the number of 
weeks with excess mortality by the standard deviation of the model 
residual.
Correlation between season excess rate of hospitalizations and in-
fluenza vaccine coverage (last column of Table 1) was measured with 
Pearson and Spearman correlation coefficient. Confidence interval for 
coefficient between the vaccine coverage and the season excess P&I 
hospitalizations rate among the individuals aged 65 years or more was 
based on bootstrap.28,29
A	significance	level	of	5%	was	considered.
3  | RESULTS
3.1 | Overall burden of influenza epidemics
A total of 395 079 P&I hospitalizations were registered between 
weeks 40/1998 and 40/2015. The seasonal average P&I excess hos-
pitalizations associated with influenza epidemics was 1932 (range 
0- 4615). This absolute value represented an average seasonal ex-
cess P&I hospitalization rate of 19.4 per 100 000 inhabitants (range 
0- 46.1/105).
The analysis of the P&I excess hospitalizations per season (Table 1, 
overall column) revealed higher absolute excess in 2004/2005 (excess 
rate of 46.1 per 100.000 inhabitants). On the other hand, in three 
seasons (2000/2001, 2002/2003 and 2005/2006) no excess P&I hos-
pitalizations were estimated.
Seasons with influenza A(H3) predominance presented the 
higher average excess absolute number and rate. Looking to the 
excess rank, the first three positions were occupied by seasons with 
A(H3) subtype predominance and the co- predominance of B and 
A(H3) occupied the forth. In the fifth position was the pandemic 
A(H1)pdm09. Seasons with influenza B predominance were the 
ones with the lowest impact. Average excess P&I hospitalization 
rates associated with influenza epidemics with A(H3) predominance 
were 3.3 and 1.4 times the average excess P&I hospitalization rate 
estimated during the influenza B predominant or co- predominant 
seasons and the influenza A(H1)pdm09 predominant seasons, 
respectively.
3.2 | Age- specific estimates
The analysis of the influenza- associated P&I excess hospitalizations 
distribution by age group, season, and predominant (sub)- type virus 
type (Table 1) revealed high heterogeneity. Statistically significant 
influenza- associated P&I excess hospitalizations were observed in all 
age groups but not for all seasons. The more extreme age groups (<2 
and	≥65	years)	presented	higher	impacts	on	seasons	with	A(H3)	pre-
dominance (Figure 2). This profile was similar to the observed during 
TABLE  1 Excess P&I hospitalization rate and absolute number per season and predominant virus type, overall and age group specific. Influenza  
vaccine coverage in the elderly
Season
Predominant 
virus
Overall <2 y 2- 5 y 5- 15 y 15- 50 y 50- 65 y ≥65 y
ICV (%) ≥65 yRate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number
Overall 19.4 (17.8- 20.0) 1932 79.8 (71.3- 83.7) 160 17.5 (13.8- 19.5) 52 5.1 (4.1- 5.7) 53 3.5 (3.0- 3.9) 167 11.2 (9.7- 11.8) 206 68.3 (62.8- 70.7) 1227
1998/99 A(H3) 35.4 (33.3- 37.4) 3451 276.6 (263.8- 289.3) 588 26.5 (22.5- 30.6) 81 2.7 (1.9- 3.6) 29 1.8 (1.3- 2.4) 90 21.1 (19.1- 23.1) 351 157.3 (149.9- 164.8) 2475 31.3
1999/00 A(H3) 25.7 (23.9- 27.5) 2529 160.8 (150.0- 171.7) 343 17.1 (13.1- 21.2) 52 7.9 (6.5- 9.2) 83 0.0 0 18.3 (16.5- 20.0) 308 93.9 (87.7- 100.2) 1525 39.0
2000/01 B 0.0 0 44.5 (36.8- 52.2) 95 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 Not available
2001/02 A(H3) 17.9 (16.2- 19.6) 1782 165.6 (154.7- 176.4) 353 23.0 (18.5- 27.6) 73 5.8 (4.7- 6.8) 61 0.0 0 12.5 (10.8- 14.3) 216 67.8 (61.6- 74.1) 1142 41.9
2002/03 B 0.0 0 0.0 0 13.5 (9.9- 17.0) 43 5.3 (4.1- 6.5) 56 0.0 0 0.0 0 0.0 0 36.9
2003/04 A(H3) 18.4 (16.7- 20.1) 1832 0.0 0 22.1 (18.0- 26.1) 71 2.1 (1.3- 3.0) 22 0.0 0 8.6 (7.1- 10.1) 151 87.2 (79.8- 94.7) 1492 47.0
2004/05 A(H3) 46.1 (43.9- 48.3) 4615 93.4 (82.6- 104.3) 192 32.6 (26.9- 38.4) 103 4.4 (3.5- 5.2) 46 6.1 (5.1- 7.1) 297 19.4 (17.3- 21.5) 347 194.9 (186.8- 203.1) 3426 39.0
2005/06a B/AH1 – – – – – – – – – – – – – – 41.6
2006/07 A(H3) 15.2 (13.8- 16.7) 1530 56.6 (47.2- 66.0) 111 10.9 (8.1- 13.8) 34 10.9 (9.7- 12.1) 114 2.0 (1.5- 2.5) 97 0.0 0 67.8 (62.0- 73.5) 1222 50.4
2007/08 B 2.3 (1.4- 3.2) 228 70.5 (61.9- 79.1) 137 16.1 (12.0- 20.2) 48 7.6 (6.2- 9.1) 80 0.0 0 0.0 0 0.0 0 51.0
2008/09 A(H3) 17.2 (15.7- 18.6) 1726 76.2 (67.6- 84.8) 146 0.0 0 0.0 0 0.0 0 5.9 (4.6- 7.3) 113 74.9 (69.6- 80.2) 1391 53.3
2009/10 A(H1)pdm09 29.3 (27.4- 31.3) 2951 123.2 (113.0- 133.4) 236 47.6 (42.7- 52.6) 140 31.8 (30- 33.6) 331 29.8 (28.7- 30.9) 1419 33.4 (31.5- 35.2) 638 0.0 0 52.2
2010/11 B/A(H1)pdm09 18.6 (16.9- 20.3) 1862 98.3 (88.8- 107.7) 182 33.3 (27.5- 39.0) 94 2.6 (1.8- 3.5) 27 8.5 (7.5- 9.5) 396 21.9 (20.0- 23.8) 428 28.3 (23.6- 33.0) 546 48.3
2011/12 A(H3) 32.5 (30.5- 34.4) 3239 37.2 (29.6- 44.9) 65 0.0 0 0.0 0 0.0 0 8.9 (7.4- 10.4) 176 140.1 (133.8- 146.3) 2748 43.4
2012/13 B/A(H1)pdm09 10.2 (8.5- 11.9) 1007 0.0 0 0.0 0 0.0 0 3.2 (2.4- 4.0) 143 8.7 (7.4- 10.0) 173 36.2 (30.0- 42.5) 724 44.9
2013/14 A(H1)pdm09 11.1 (9.4- 12.8) 1100 74.4 (64.9- 83.8) 117 37.2 (32.2- 42.2) 101 0.0 0 5.2 (4.3- 6.2) 232 5.7 (4.6- 6.8) 114 8.5 (5.1- 11.8) 172 49.9
2014/15 B 31.0 (29.0- 33.0) 3060 0.0 0 0.0 0 0.0 0 0.0 0 14.1 (12.5- 15.7) 282 136.0 (128.6- 143.5) 2766 50.9
aNo influenza activity in this season.
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influenza B predominant seasons. The average excess P&I hospitali-
zation rates for A(H3) seasons was higher than influenza B seasons 
for all age groups with exception for those in the 15- 50 age group 
(Figure 3).
A very different distribution of the excess P&I hospitaliza-
tion rate was registered for the influenza A(H1)pdm09 predom-
inant seasons, the highest rate being observed for the <2- year 
age group. Considering the age group for which the vaccine is 
recommended	(≥65	years),	the	lowest	average	excess	P&I	hospi-
talization rate, per predominant (sub)- type influenza season, was 
observed during the pandemic season (Figure 4). Nevertheless, 
for the individuals with age between 5 and 64 years it was during 
the pandemic that the highest excess P&I hospitalization rates 
were observed in particular for the age group 5- 49 in which the 
rate was 10 times the average rate for the influenza B predomi-
nant seasons.
F IGURE  2 Average excess P&I hospitalization rates per 
predominant (sub)- type of influenza virus by age group
F IGURE  3 Average excess P&I hospitalization rates ratios for 
A(H3) and A(H1)pdm09 predominant (sub)- type of influenza virus 
compared to B predominant seasons by age group
TABLE  1 Excess P&I hospitalization rate and absolute number per season and predominant virus type, overall and age group specific. Influenza  
vaccine coverage in the elderly
Season
Predominant 
virus
Overall <2 y 2- 5 y 5- 15 y 15- 50 y 50- 65 y ≥65 y
ICV (%) ≥65 yRate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number Rate (CI 95%) Number
Overall 19.4 (17.8- 20.0) 1932 79.8 (71.3- 83.7) 160 17.5 (13.8- 19.5) 52 5.1 (4.1- 5.7) 53 3.5 (3.0- 3.9) 167 11.2 (9.7- 11.8) 206 68.3 (62.8- 70.7) 1227
1998/99 A(H3) 35.4 (33.3- 37.4) 3451 276.6 (263.8- 289.3) 588 26.5 (22.5- 30.6) 81 2.7 (1.9- 3.6) 29 1.8 (1.3- 2.4) 90 21.1 (19.1- 23.1) 351 157.3 (149.9- 164.8) 2475 31.3
1999/00 A(H3) 25.7 (23.9- 27.5) 2529 160.8 (150.0- 171.7) 343 17.1 (13.1- 21.2) 52 7.9 (6.5- 9.2) 83 0.0 0 18.3 (16.5- 20.0) 308 93.9 (87.7- 100.2) 1525 39.0
2000/01 B 0.0 0 44.5 (36.8- 52.2) 95 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 Not available
2001/02 A(H3) 17.9 (16.2- 19.6) 1782 165.6 (154.7- 176.4) 353 23.0 (18.5- 27.6) 73 5.8 (4.7- 6.8) 61 0.0 0 12.5 (10.8- 14.3) 216 67.8 (61.6- 74.1) 1142 41.9
2002/03 B 0.0 0 0.0 0 13.5 (9.9- 17.0) 43 5.3 (4.1- 6.5) 56 0.0 0 0.0 0 0.0 0 36.9
2003/04 A(H3) 18.4 (16.7- 20.1) 1832 0.0 0 22.1 (18.0- 26.1) 71 2.1 (1.3- 3.0) 22 0.0 0 8.6 (7.1- 10.1) 151 87.2 (79.8- 94.7) 1492 47.0
2004/05 A(H3) 46.1 (43.9- 48.3) 4615 93.4 (82.6- 104.3) 192 32.6 (26.9- 38.4) 103 4.4 (3.5- 5.2) 46 6.1 (5.1- 7.1) 297 19.4 (17.3- 21.5) 347 194.9 (186.8- 203.1) 3426 39.0
2005/06a B/AH1 – – – – – – – – – – – – – – 41.6
2006/07 A(H3) 15.2 (13.8- 16.7) 1530 56.6 (47.2- 66.0) 111 10.9 (8.1- 13.8) 34 10.9 (9.7- 12.1) 114 2.0 (1.5- 2.5) 97 0.0 0 67.8 (62.0- 73.5) 1222 50.4
2007/08 B 2.3 (1.4- 3.2) 228 70.5 (61.9- 79.1) 137 16.1 (12.0- 20.2) 48 7.6 (6.2- 9.1) 80 0.0 0 0.0 0 0.0 0 51.0
2008/09 A(H3) 17.2 (15.7- 18.6) 1726 76.2 (67.6- 84.8) 146 0.0 0 0.0 0 0.0 0 5.9 (4.6- 7.3) 113 74.9 (69.6- 80.2) 1391 53.3
2009/10 A(H1)pdm09 29.3 (27.4- 31.3) 2951 123.2 (113.0- 133.4) 236 47.6 (42.7- 52.6) 140 31.8 (30- 33.6) 331 29.8 (28.7- 30.9) 1419 33.4 (31.5- 35.2) 638 0.0 0 52.2
2010/11 B/A(H1)pdm09 18.6 (16.9- 20.3) 1862 98.3 (88.8- 107.7) 182 33.3 (27.5- 39.0) 94 2.6 (1.8- 3.5) 27 8.5 (7.5- 9.5) 396 21.9 (20.0- 23.8) 428 28.3 (23.6- 33.0) 546 48.3
2011/12 A(H3) 32.5 (30.5- 34.4) 3239 37.2 (29.6- 44.9) 65 0.0 0 0.0 0 0.0 0 8.9 (7.4- 10.4) 176 140.1 (133.8- 146.3) 2748 43.4
2012/13 B/A(H1)pdm09 10.2 (8.5- 11.9) 1007 0.0 0 0.0 0 0.0 0 3.2 (2.4- 4.0) 143 8.7 (7.4- 10.0) 173 36.2 (30.0- 42.5) 724 44.9
2013/14 A(H1)pdm09 11.1 (9.4- 12.8) 1100 74.4 (64.9- 83.8) 117 37.2 (32.2- 42.2) 101 0.0 0 5.2 (4.3- 6.2) 232 5.7 (4.6- 6.8) 114 8.5 (5.1- 11.8) 172 49.9
2014/15 B 31.0 (29.0- 33.0) 3060 0.0 0 0.0 0 0.0 0 0.0 0 14.1 (12.5- 15.7) 282 136.0 (128.6- 143.5) 2766 50.9
aNo influenza activity in this season.
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3.3 | Association between influenza vaccine 
coverage and seasonal excess P&I influenza- associated 
hospitalization rates among the elderly
The overall correlation between the influenza vaccine coverage 
and	 the	 seasonal	 P&I	 excess	 hospitalizations	 rate	 was	 −0.381	 (95%	 
CI:	−0.750	to	0.226)	measured	with	Pearson	correlation	and	−0.306	(95%	
CI:	−0.766	to	0.332)	with	the	Spearmen	correlation.	When	the	analysis	
was restricted to seasons with influenza A(H3) predominance, the corre-
lation	coefficient	was	stronger	(−0.653;	95%	CI:	−0.950	to	−0.137	using	
Pearson	and	−0.675;	95%	CI:	−1.000	to	0.025	with	Spearman).
4  | DISCUSSION
The present study is the first Portuguese comprehensive analysis 
aimed at estimating the excess of pneumonia and influenza hospi-
talizations associated with influenza epidemics, using a wide period of 
analysis that encompasses 17 influenza seasons. This study estimated 
an average of 1932 seasonal excess P&I hospitalizations associated 
with influenza epidemics. This estimate varied widely across the 17 
seasons from no excess (in 2000/2001, 2002/2003, and 2005/2006 
seasons) to a maximum of 4615 excess P&I hospitalizations (2004/05 
season). Taking into account the population, these estimates repre-
sented a seasonal excess P&I hospitalizations rate of 19.4 per 100 000 
habitants reaching a maximum of 46.1 per 100 000 habitants. Our 
overall estimated P&I influenza- associated excess hospitalization rate 
was in the agreement with the reported estimates in other studies.30
Overall, seasonal P&I excess hospitalization rates were higher 
among the individuals with <2 years and among those with 65 or 
more years of age. These results are compatible with those published 
in other studies that include these two groups at higher risk of being 
hospitalized during influenza seasonal epidemics.3,31,32 Nevertheless, 
this pattern was not equal in all seasons, specifically during the pan-
demic A(H1)pdm09 season, where no excess P&I hospitalizations were 
observed	among	the	elderly	(≥65	years).	On	the	other	hand,	the	excess	
P&I hospitalization was the highest observed within the individuals 
aged between 2 and 65 years, a population group that, during sea-
sonal influenza epidemics, presented the lowest influenza- associated 
excess P&I hospitalization rates. This observation was consistent with 
other European studies30,33-35 and with mortality profile of the pan-
demic A(H1)pdm09 in Portugal.22 According to some authors,36,37 the 
elderly population was largely spared during the pandemic mainly due 
to their past exposure to influenza virus similar to the A(H1N1)pdm09 
virus and younger age groups were naive to this new circulating virus. 
This fact was reflected in the recommendations issued by health au-
thorities regarding the pandemic monovalent vaccine uptake that did 
not include the individuals aged 65 or more years of age.38,39
The excess P&I hospitalizations profile was maintained in seasons 
with predominance circulation of A(H3) and B virus. Seasons with 
A(H3) influenza virus subtype predominance presented on average a 
higher excess P&I influenza- associated hospitalization rate, among the 
extreme age groups. Comparing with seasons with other virological 
profile, A(H3) predominant seasons, presented a P&I excess hospital-
ization rate, among the younger (<2 years), very similar to the A(H1)
pdm09 age group but higher than B or B/A(H1)pdm09 seasons. A(H3) 
also had much higher impact on the elderly age group compared to 
the other virus profiles. This result has been largely described in other 
study,5 targeting these two age groups as the ones with the highest 
impact of influenza- associated hospitalizations and in particular when 
influenza A(H3) subtype is predominant. The previously described 
excess P&I mortality rate profile in Portugal8 has showed a different 
profile, with small or no impact among the younger age groups con-
trasting with higher excess P&I mortality rate for the age groups above 
65 years or more. These results are in line with an expected higher 
influenza lethality rate among the older age groups.
In this study, among the individuals with 65 or more years of age, 
a negative correlation was observed between the seasonal influenza 
vaccine coverage and seasonal P&I excess hospitalizations during the 
influenza epidemics. This negative correlation was not statistical signif-
icant	when	all	seasons	were	considered	(Pearson	correlation	=	−0.381);	
however, statistical significance was observed when considering only 
seasons with influenza A(H3) subtype predominance (Pearson correla-
tion	=	−0.653).	One	possible	reason	for	the	increased	strength	in	the	
correlation can be related to fact that the other seasons had a low 
impact in this age group. When considering all seasons, an increased 
dispersion was observed, reducing the strength correlation. Among the 
elderly	(≥65	years),	a	negative	correlation	was	also	previously	observed	
in another study that measured the correlation between vaccine cover-
age and seasonal ILI attack rates, and published a spearman rank coef-
ficient	of	−0.359	and	−0.899,	respectively,	for	all	seasons	and	only	for	
the A(H3) predominant.19 In 2016, a study that included 14 European 
Union countries, including Portugal,40 has analyzed the correlation be-
tween seasonal ILI incidence rates and vaccine coverage among all the 
population (except for individuals with 65 or more years of age) and 
F IGURE  4 Scatter plot of the vaccine coverage rates vs the 
excess P&I hospitalizations rate according to the dominant subtype 
virus for seasons 1998/1999- 2014/2015, on individuals aged 65 y 
or more
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showed no consistent results between the countries, identifying only 
negative	correlation	among	the	elderly	population	for	England	(−0.80),	
the	Netherlands	(−0.60),	and	Germany	(−0.57).	For	Portugal,	the	study	
included seasons 1998- 1999 to 2013- 2014 showing correlation co-
efficients different from those obtained in our previous study that in-
cluded seasons 1998- 1999 to 2006- 2007.19 A possible explanation for 
the difference may be the data source for ILI rates, that is, the use of 
provisory ILI rates (in the European study) and definitive rates calcu-
lated in the end of the season (in the national study).
The results presented in the this study must be interpreted in light 
of the methods and data limitations. A time series ecological method 
was used to estimate the seasonal P&I excess hospitalization rates in 
the study period. As such, the excess P&I hospitalization rate cannot 
be considered fully attributable to influenza epidemics but only associ-
ated with the occurrence of the epidemics. Other covariates as the cir-
culation of other respiratory virus, like the respiratory syncytial virus, 
were not considered in the model. This fact could have overestimated 
the impact of the influenza epidemics reported in the present report, 
mainly for the younger age groups (<2 years).41,42 Nevertheless, when 
stratified by influenza virological profile, there were differences be-
tween A(H3), A(H1)pmd09, or B predominant seasons, data consistent 
with previous reports, which suggests that P&I excess hospitalizations 
were sensible and probably specific in capturing the impact of the in-
fluenza epidemics. In this study, an ARIMA model was used and no 
information about virus type or subtype circulation was considered. 
Unlike previous studies,12,42 the weekly distribution of the influenza 
virus detection was not included as covariate in the model. This fact 
did not allow for estimation of the excess P&I influenza- associated 
hospitalization by (sub)- type influenza virus. However, according to 
Thompson et al,10 similar influenza- associated mortality was obtained 
using ARIMA or Poisson models that included influenza type as co-
variate. This study also highlighted that, in the absence of robust co-
variates data, namely on weekly influenza type and subtype data in 
specific age groups, ARIMA models are a good candidate model to be 
used in influenza- associated excess studies.10
Finally, our study did not take into consideration the correlation 
between circulating influenza virus and vaccine strains. This could 
have implications on the correlation estimates between vaccine cov-
erage and influenza- associated P&I hospitalizations.
In summary, our type/subtype and age- specific influenza- 
associated P&I hospitalizations are in accordance with the literature 
on influenza excess hospitalization and provide for the first time a 
measure of the impact of influenza in Portugal for a wide period. Also, 
this study evidences that there is a negative correlation between 
influenza vaccination and the influenza- associated P&I hospitaliza-
tions, in particular when A(H3) is circulating and in the risk group of 
the elderly for which the vaccine is recommended. These results are 
encouraging, specially to validate campaigns for vaccine uptake in 
seasonal epidemics and in specific age groups in a future pandemic. 
Nevertheless, more studies should be performed to evaluate the con-
sistency of these results. Following this line of thought, it is important 
to continue researches in Portugal by looking into other hospitaliza-
tions causes and by incorporating additional information on influenza 
type/subtype circulation as well as other respiratory virus as a way to 
fortify these findings.
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